Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

GM1 ganglioside in Parkinson's disease: Results of a five year open study.

Schneider JS, Sendek S, Daskalakis C, Cambi F.

J Neurol Sci. 2010 May 15;292(1-2):45-51. doi: 10.1016/j.jns.2010.02.009. Epub 2010 Mar 5.

PMID:
20206941
2.

Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.

Schneider JS, Roeltgen DP, Mancall EL, Chapas-Crilly J, Rothblat DS, Tatarian GT.

Neurology. 1998 Jun;50(6):1630-6.

PMID:
9633704
3.

GM1 ganglioside in the treatment of Parkinson's disease.

Schneider JS.

Ann N Y Acad Sci. 1998 Jun 19;845:363-73.

PMID:
9668369
4.

GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.

Schneider JS, Roeltgen DP, Rothblat DS, Chapas-Crilly J, Seraydarian L, Rao J.

Neurology. 1995 Jun;45(6):1149-54.

PMID:
7783880
5.

A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.

Jankovic J, Hunter C.

Parkinsonism Relat Disord. 2002 Mar;8(4):271-6.

PMID:
12039422
7.

The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.

Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P; Parkinson-Control Study Group.

Mov Disord. 2006 Apr;21(4):500-9.

PMID:
16267842
8.

A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W.

J Neurol Sci. 2013 Jan 15;324(1-2):140-8. doi: 10.1016/j.jns.2012.10.024. Epub 2012 Nov 28.

9.

Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease.

Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, Olanow CW.

Arch Neurol. 1999 Feb;56(2):179-87.

PMID:
10025423
10.

Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.

Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S, Kulisevsky J, Albanese A, Volkmann J, Hariz MI, Quinn NP, Speelman JD, Guridi J, Zamarbide I, Gironell A, Molet J, Pascual-Sedano B, Pidoux B, Bonnet AM, Agid Y, Xie J, Benabid AL, Lozano AM, Saint-Cyr J, Romito L, Contarino MF, Scerrati M, Fraix V, Van Blercom N.

Brain. 2005 Oct;128(Pt 10):2240-9. Epub 2005 Jun 23.

PMID:
15975946
11.

The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.

Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.

Clin Ther. 2009 Jan;31(1):89-98. doi: 10.1016/j.clinthera.2009.01.012. Erratum in: Clin Ther. 2009 Mar;31(3):677.

PMID:
19243709
12.
13.

The relationships between the unified Parkinson's disease rating scale and lower extremity functional performance in persons with early-stage Parkinson's disease.

Song J, Fisher BE, Petzinger G, Wu A, Gordon J, Salem GJ.

Neurorehabil Neural Repair. 2009 Sep;23(7):657-61. doi: 10.1177/1545968309332878. Epub 2009 Mar 31.

PMID:
19336530
14.

Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.

Alvarez L, Macias R, Lopez G, Alvarez E, Pavon N, Rodriguez-Oroz MC, Juncos JL, Maragoto C, Guridi J, Litvan I, Tolosa ES, Koller W, Vitek J, DeLong MR, Obeso JA.

Brain. 2005 Mar;128(Pt 3):570-83. Epub 2005 Feb 2.

PMID:
15689366
15.

Reoperation for suboptimal outcomes after deep brain stimulation surgery.

Ellis TM, Foote KD, Fernandez HH, Sudhyadhom A, Rodriguez RL, Zeilman P, Jacobson CE 4th, Okun MS.

Neurosurgery. 2008 Oct;63(4):754-60; discussion 760-1. doi: 10.1227/01.NEU.0000325492.58799.35.

PMID:
18981887
16.

The long-term safety and efficacy of pramipexole in advanced Parkinson's disease.

Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Beck B, Paume D, Doyle C.

Parkinsonism Relat Disord. 2001 Apr;7(2):115-120.

PMID:
11248592
17.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
18.

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.

Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE.

Mov Disord. 2007 Dec;22(16):2409-17.

PMID:
17894339
19.
20.

Supplemental Content

Support Center